TRCT
DRUG

Tower Research Capital (TRC)’s Bright Minds Biosciences DRUG Stock Holding History

Tower Research Capital (TRC)’s Portfolio DRUG Stock Details DRUG Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2026
Q2 		$71K Buy
1,011
+414
+69% +$32.5K ﹤0.01% 2463
2026
Q1 		$43.6K Sell
597
-485
-45% -$39K ﹤0.01% 2868
2025
Q4 		$84.4K Buy
1,082
+811
+299% +$54.2K ﹤0.01% 2050
2025
Q3 		$16.4K Buy
+271
New +$10.5K ﹤0.01% 3476
2022
Q4 		– Sell
-126
Closed -$1K – 5974
2022
Q3 		$1K Buy
+126
New +$817 ﹤0.01% 5753

Other funds holding DRUG

JT
Jupiter Topco New York $245B AUM
CAM
Cormorant Asset Management Boston, Massachusetts $1.95B AUM 773.9% 1-Year Est. Return
BlackRock
BlackRock New York $6.73T AUM 46.02% 1-Year Est. Return
VC
Vivo Capital Palo Alto, California $1.1B AUM 799.93% 1-Year Est. Return
VPC
Vestal Point Capital New York $4.28B AUM 239% 1-Year Est. Return
B
Braidwell Stamford, Connecticut $2.7B AUM 88.53% 1-Year Est. Return
DCM
Driehaus Capital Management Chicago, Illinois $17.3B AUM 211.34% 1-Year Est. Return
Balyasny Asset Management
Balyasny Asset Management Chicago, Illinois $80.2B AUM 51.53% 1-Year Est. Return
Adage Capital Partners
Adage Capital Partners Boston, Massachusetts $71.3B AUM 56.8% 1-Year Est. Return
Point72 Asset Management
Point72 Asset Management Stamford, Connecticut $90.7B AUM 77.13% 1-Year Est. Return

Tower Research Capital (TRC)'s DRUG Position: Q2 2026 in Review

Tower Research Capital (TRC) increased its Bright Minds Biosciences (DRUG) stake by 69% in Q2 2026, buying an estimated $32.5K and bringing the position to 1,011 shares worth $71K. The position accounts for ﹤0.01% of the portfolio, ranked #2463.

Tower Research Capital (TRC) first reported a position in DRUG in Q3 2022 and has held it in 5 quarters since. The position peaked at $84.4K in Q4 2025. 99 funds tracked by Wall St. Rank hold DRUG as of Q2 2026.

  • Tower Research Capital (TRC) held 1,011 shares of Bright Minds Biosciences worth $71K as of Q2 2026.
  • Tower Research Capital (TRC) bought 414 Bright Minds Biosciences shares in Q2 2026, an estimated $32.5K.
  • Bright Minds Biosciences made up ﹤0.01% of Tower Research Capital (TRC)'s portfolio in Q2 2026, its #2463 holding.
  • Tower Research Capital (TRC) first reported a position in Bright Minds Biosciences in Q3 2022 and has held it in 5 quarters since.
  • Tower Research Capital (TRC)'s Bright Minds Biosciences position peaked at $84.4K in Q4 2025.
  • 99 funds tracked by Wall St. Rank held Bright Minds Biosciences as of Q2 2026.

Based on Tower Research Capital (TRC)'s 13F filing for Q2 2026, filed 11 Aug 2026.